| General Information of Drug Metabolite (DM) (ID: DM005684) |
| DM Name |
ABT-263 metabolite
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
ABT-263
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| ABT-263 |
DR1839
|
Phase 2 |
Ovarian cancer |
|
|
| References |
| 1 |
Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014 Dec;39(6):680-4.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
